SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer of Cell Genesys, will present a company
update at the Lehman Brothers Ninth Annual Global Healthcare Conference in
South Beach, FL that will be broadcast live over the internet on Thursday,
March 9, 2006, at 5:15 PM EST.
The webcast presentation will be available on the Investor Relations
section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable
to listen to the live webcast, it will be archived on the site for at least 72
hours following the presentation. To access the replay, go to the Investor
Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase 1
trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys
continues to hold an equity interest in its former subsidiary, Ceregene, Inc.,
which is developing gene therapies for neurodegenerative disorders. Cell
Genesys is headquartered in South San Francisco, CA and has its principal
manufacturing operation in Hayward, CA. For additional information, please
visit the company's website at http://www.cellgenesys.com.
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials and research and development programs, the regulatory approval process
for clinical trials, competitive technologies and products, patents,
continuation of corporate partnerships and the need for additional financings.
For information about these and other risks which may affect Cell Genesys,
please see the company's Annual Report on Form 10-K for the year ended
December 31, 2004 filed on March 14, 2005 as well as Cell Genesys' reports on
Form 10-Q and 8-K and other reports filed from time to time with the
Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations
Cell Genesys, Inc.
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
Inc., +1-650-266-3200
|
